Description
Oxaliplatin-Tchaikapharma is an antineoplastic or anticancer drug and contains platinum. The active ingredient of Oxaliplatin-Tchaikapharma is oxaliplatin.
Indications
Oxaliplatin-Tchaikapharma is used to treat cancer of the large bowel (treatment of stage III colon cancer after complete resection of primary tumour, metastatic cancer of colon and rectum).
Subject to medical prescription.
Concentration and pharmaceutical form: 50 mg, 100 mg powder for solution for infusion
Description
Meropenem-Tchaikapharma belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections.
Indications
Meropenem-Tchaikapharma is used to treat the following infections:
– Infection affecting the lungs (pneumonia);
– Lung and bronchial infections in patients suffering from cystic fibrosis;
– Complicated urinary tract infections;
– Complicated infections in the abdomen;
– Infections that you can catch during or after the delivery;
– Complicated skin and soft tissues infections;
– Acute bacterial infection of the brain (meningitis).
Subject to medical prescription.
Concentration and pharmaceutical form: 1 g powder for solution for injection/infusion
Description
Gemcitabine belongs to a group of medicines called cytotoxic agents. These drugs kill dividing cells, including cancer cells.
Indications
– Treatment of locally advanced or metastatic bladder cancer in combination with Cisplatin.
– Treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
– In combination with Cisplatin it is indicated for first-line treatment of patients with locally advanced or metastatic non-small-cell lung carcinoma (NSCLC).
– Treatment of locally advanced or metastatic epithelial ovarian cancer in combination with Carboplatin in patients with relapsed disease after a remission of at least 6 months after first-line treatment of platinum-based.
– In combination with Paclitaxel it is indicated for treatment of patients with nonresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.
Subject to medical prescription
Pharmaceutical form: 200 mg powder for solution for infusion
Pharmaceutical form: 1000 mg powder for solution for infusion
Description
Valsartan belongs to a group of medicines called angiotensin II receptor blockers”, whose effect is expressed in blood vessels and blood pressure.
Indications
– Fresh (12 hours – 10 days) myocardial infarction
– Heart failure
– Hypertension
Subject to medical prescription
Pharmaceutical form: 160 mg x 30 film-coated tablets
NHIF code: CF991
ICD: I10, I11.0, I11.9, I12.0, I12.9, I13.0, I13.1, I13.2, I25.5, I50.0, I50.1
